Assessment	B:C0220825
of	O
IL	O
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	O
Polymorphisms	O
in	O
a	O
Cohort	O
of	O
Cuban	O
Chronic	O
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Assessment	O
of	O
IL	B:C1425475
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	O
Polymorphisms	O
in	O
a	O
Cohort	O
of	O
Cuban	O
Chronic	O
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Assessment	O
of	O
IL	O
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	B:C0678941
Polymorphisms	O
in	O
a	O
Cohort	O
of	O
Cuban	O
Chronic	O
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Assessment	O
of	O
IL	O
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	O
Polymorphisms	B:C0032529
in	O
a	O
Cohort	O
of	O
Cuban	O
Chronic	O
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Assessment	O
of	O
IL	O
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	O
Polymorphisms	O
in	O
a	O
Cohort	B:C0599755
of	O
Cuban	O
Chronic	O
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Assessment	O
of	O
IL	O
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	O
Polymorphisms	O
in	O
a	O
Cohort	O
of	O
Cuban	B:C1553379
Chronic	O
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Assessment	O
of	O
IL	O
-	I:C1425475
28	I:C1425475
:	O
rs12979860	O
and	O
rs8099917	O
Polymorphisms	O
in	O
a	O
Cohort	O
of	O
Cuban	O
Chronic	B:C4049394
HCV	I:C4049394
Genotype	I:C4049394
1	I:C4049394
b	I:C4049394
Patients	O
.	O

Hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
(	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
)	O
is	O
a	O
significant	O
global	O
public	O
health	O
problem	O
with	O
>	O
185	O
million	O
infections	O
worldwide	O
.	O

Hepatitis	O
C	I:C0220847
virus	I:C0220847
(	O
Hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
)	O
is	O
a	O
significant	O
global	O
public	O
health	O
problem	O
with	O
>	O
185	O
million	O
infections	O
worldwide	O
.	O

Hepatitis	O
C	I:C0220847
virus	I:C0220847
(	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
)	O
is	O
a	O
significant	O
global	O
public	O
health	O
problem	O
with	O
>	O
185	O
million	O
infections	B:C3714514
worldwide	O
.	O

Hepatitis	O
C	I:C0220847
virus	I:C0220847
(	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
)	O
is	O
a	O
significant	O
global	O
public	O
health	O
problem	O
with	O
>	O
185	O
million	O
infections	O
worldwide	B:C2700280
.	O

A	O
series	O
of	O
genome	B:C2350277
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	O
-	I:C1425475
28B	I:C1425475
polymorphisms	O
as	O
a	O
predictor	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
(	O
sustained	O
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	O
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

A	O
series	O
of	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	B:C2350277
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	O
-	I:C1425475
28B	I:C1425475
polymorphisms	O
as	O
a	O
predictor	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
(	O
sustained	O
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	O
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

A	O
series	O
of	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	B:C1425475
-	I:C1425475
28B	I:C1425475
polymorphisms	O
as	O
a	O
predictor	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
(	O
sustained	O
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	O
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

A	O
series	O
of	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	O
-	I:C1425475
28B	I:C1425475
polymorphisms	B:C0032529
as	O
a	O
predictor	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
(	O
sustained	O
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	O
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

A	O
series	O
of	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	O
-	I:C1425475
28B	I:C1425475
polymorphisms	O
as	O
a	O
predictor	O
of	O
sustained	B:C4050171
virologic	I:C4050171
response	I:C4050171
(	O
sustained	O
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	O
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

A	O
series	O
of	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	O
-	I:C1425475
28B	I:C1425475
polymorphisms	O
as	O
a	O
predictor	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
(	O
sustained	B:C4050171
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	O
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

A	O
series	O
of	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
(	O
genome	O
-	I:C2350277
wide	I:C2350277
association	I:C2350277
studies	I:C2350277
)	O
has	O
identified	O
IL	O
-	I:C1425475
28B	I:C1425475
polymorphisms	O
as	O
a	O
predictor	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
(	O
sustained	O
virologic	I:C4050171
response	I:C4050171
)	O
,	O
as	O
well	O
as	O
spontaneous	O
clearance	O
in	O
chronic	B:C4049394
HCV	I:C4049394
genotype	I:C4049394
1	I:C4049394
patients	O
.	O

The	O
objective	B:C0018017
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
IL	O
-	O
28B	O
rs12979860	O
and	O
rs8099917	O
polymorphisms	O
in	O
Cuban	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
evaluate	B:C0220825
the	O
prevalence	O
of	O
IL	O
-	O
28B	O
rs12979860	O
and	O
rs8099917	O
polymorphisms	O
in	O
Cuban	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
IL	O
-	O
28B	O
rs12979860	O
and	O
rs8099917	B:C0678941
polymorphisms	O
in	O
Cuban	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
IL	O
-	O
28B	O
rs12979860	O
and	O
rs8099917	O
polymorphisms	B:C0032529
in	O
Cuban	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
IL	O
-	O
28B	O
rs12979860	O
and	O
rs8099917	O
polymorphisms	O
in	O
Cuban	B:C1553379
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
prevalence	O
of	O
IL	O
-	O
28B	O
rs12979860	O
and	O
rs8099917	O
polymorphisms	O
in	O
Cuban	O
chronic	O
Hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
patients	O
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	B:C0332293
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	B:C1533734
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	B:C3851847
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	B:C0002199
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	B:C0035525
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	B:C0002199
/	O
R	O
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	B:C0035525
)	O
antiviral	O
therapy	I:C0280274
.	O

The	O
study	O
cohort	O
included	O
73	O
chronic	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
patients	O
treated	O
with	I:C0332293
concomitant	O
administration	O
of	O
CIGB	O
-	I:C3851847
230	I:C3851847
and	O
nonpegylated	O
IFN	I:C0002199
-α	I:C0002199
plus	O
ribavirin	O
(	O
non-pegIFN-α	O
/	O
R	O
)	O
antiviral	B:C0280274
therapy	I:C0280274
.	O

The	O
genotype	O
distribution	O
of	O
IL	B:C0678941
-	I:C0678941
28B	I:C0678941
rs12979860	I:C0678941
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
was	O
29	O
,	O
41	O
,	O
and	O
30	O
%	O
,	O
respectively	O
,	O
and	O
the	O
distribution	O
for	O
rs8099917TT	O
,	O
-	O
TG	O
,	O
and	O
-	O
GG	O
was	O
63	O
,	O
31	O
,	O
and	O
5	O
%	O
,	O
respectively	O
.	O

The	O
genotype	O
distribution	O
of	O
IL	O
-	I:C0678941
28B	I:C0678941
rs12979860	I:C0678941
CC	I:C0678941
,	O
-	O
CT	B:C0678941
,	O
and	O
-	O
TT	O
was	O
29	O
,	O
41	O
,	O
and	O
30	O
%	O
,	O
respectively	O
,	O
and	O
the	O
distribution	O
for	O
rs8099917TT	O
,	O
-	O
TG	O
,	O
and	O
-	O
GG	O
was	O
63	O
,	O
31	O
,	O
and	O
5	O
%	O
,	O
respectively	O
.	O

The	O
genotype	O
distribution	O
of	O
IL	O
-	I:C0678941
28B	I:C0678941
rs12979860	I:C0678941
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	B:C0678941
was	O
29	O
,	O
41	O
,	O
and	O
30	O
%	O
,	O
respectively	O
,	O
and	O
the	O
distribution	O
for	O
rs8099917TT	O
,	O
-	O
TG	O
,	O
and	O
-	O
GG	O
was	O
63	O
,	O
31	O
,	O
and	O
5	O
%	O
,	O
respectively	O
.	O

The	O
genotype	O
distribution	O
of	O
IL	O
-	I:C0678941
28B	I:C0678941
rs12979860	I:C0678941
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
was	O
29	O
,	O
41	O
,	O
and	O
30	O
%	O
,	O
respectively	O
,	O
and	O
the	O
distribution	O
for	O
rs8099917TT	B:C0678941
,	O
-	O
TG	O
,	O
and	O
-	O
GG	O
was	O
63	O
,	O
31	O
,	O
and	O
5	O
%	O
,	O
respectively	O
.	O

The	O
genotype	O
distribution	O
of	O
IL	O
-	I:C0678941
28B	I:C0678941
rs12979860	I:C0678941
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
was	O
29	O
,	O
41	O
,	O
and	O
30	O
%	O
,	O
respectively	O
,	O
and	O
the	O
distribution	O
for	O
rs8099917TT	O
,	O
-	O
TG	B:C0678941
,	O
and	O
-	O
GG	O
was	O
63	O
,	O
31	O
,	O
and	O
5	O
%	O
,	O
respectively	O
.	O

The	O
genotype	O
distribution	O
of	O
IL	O
-	I:C0678941
28B	I:C0678941
rs12979860	I:C0678941
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
was	O
29	O
,	O
41	O
,	O
and	O
30	O
%	O
,	O
respectively	O
,	O
and	O
the	O
distribution	O
for	O
rs8099917TT	O
,	O
-	O
TG	O
,	O
and	O
-	O
GG	B:C0678941
was	O
63	O
,	O
31	O
,	O
and	O
5	O
%	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
for	O
rs12979860C	B:C0678941
and	O
-	O
T	O
alleles	O
were	O
51	O
and	O
49	O
%	O
,	O
respectively	O
,	O
and	O
for	O
rs8099917G	O
and	O
-	O
T	O
alleles	O
,	O
the	O
values	O
were	O
21	O
and	O
79	O
%	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
for	O
rs12979860C	O
and	O
-	O
T	B:C0678941
alleles	O
were	O
51	O
and	O
49	O
%	O
,	O
respectively	O
,	O
and	O
for	O
rs8099917G	O
and	O
-	O
T	O
alleles	O
,	O
the	O
values	O
were	O
21	O
and	O
79	O
%	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
for	O
rs12979860C	O
and	O
-	O
T	O
alleles	B:C0002085
were	O
51	O
and	O
49	O
%	O
,	O
respectively	O
,	O
and	O
for	O
rs8099917G	O
and	O
-	O
T	O
alleles	O
,	O
the	O
values	O
were	O
21	O
and	O
79	O
%	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
for	O
rs12979860C	O
and	O
-	O
T	O
alleles	O
were	O
51	O
and	O
49	O
%	O
,	O
respectively	O
,	O
and	O
for	O
rs8099917G	B:C0678941
and	O
-	O
T	O
alleles	O
,	O
the	O
values	O
were	O
21	O
and	O
79	O
%	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
for	O
rs12979860C	O
and	O
-	O
T	O
alleles	O
were	O
51	O
and	O
49	O
%	O
,	O
respectively	O
,	O
and	O
for	O
rs8099917G	O
and	O
-	O
T	B:C0678941
alleles	O
,	O
the	O
values	O
were	O
21	O
and	O
79	O
%	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
for	O
rs12979860C	O
and	O
-	O
T	O
alleles	O
were	O
51	O
and	O
49	O
%	O
,	O
respectively	O
,	O
and	O
for	O
rs8099917G	O
and	O
-	O
T	O
alleles	B:C0002085
,	O
the	O
values	O
were	O
21	O
and	O
79	O
%	O
,	O
respectively	O
.	O

sustained	B:C4050171
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	O
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	O
,	O
-	O
GT	O
,	O
and	O
-	O
GG	O
,	O
respectively	O
.	O

sustained	O
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	B:C0678941
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	O
,	O
-	O
GT	O
,	O
and	O
-	O
GG	O
,	O
respectively	O
.	O

sustained	O
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	O
CC	I:C0678941
,	O
-	O
CT	B:C0678941
,	O
and	O
-	O
TT	O
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	O
,	O
-	O
GT	O
,	O
and	O
-	O
GG	O
,	O
respectively	O
.	O

sustained	O
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	O
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	B:C0678941
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	O
,	O
-	O
GT	O
,	O
and	O
-	O
GG	O
,	O
respectively	O
.	O

sustained	O
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	O
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	B:C0678941
,	O
-	O
GT	O
,	O
and	O
-	O
GG	O
,	O
respectively	O
.	O

sustained	O
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	O
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	O
,	O
-	O
GT	B:C0678941
,	O
and	O
-	O
GG	O
,	O
respectively	O
.	O

sustained	O
virologic	I:C4050171
response	I:C4050171
rates	O
were	O
55	O
,	O
42	O
,	O
and	O
35	O
%	O
for	O
rs12979860	O
CC	I:C0678941
,	O
-	O
CT	O
,	O
and	O
-	O
TT	O
,	O
respectively	O
,	O
and	O
52	O
,	O
30	O
,	O
and	O
25	O
%	O
for	O
rs8099917TT	O
,	O
-	O
GT	O
,	O
and	O
-	O
GG	B:C0678941
,	O
respectively	O
.	O

The	O
combined	O
assessment	B:C0220825
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	B:C0752046
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	B:C0752046
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	B:C0678941
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	B:C0678941
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	B:C0678941
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	B:C0678941
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	B:C0678941
/	O
rs8099917GG	O
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

The	O
combined	O
assessment	O
of	O
both	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
resulted	O
in	O
3	O
major	O
genotypes	O
(	O
rs12979860	O
CC	I:C0678941
/	O
rs8099917TT	O
,	O
rs12979860CT	O
/	O
rs8099917TT	O
,	O
and	O
rs12979860CT	O
/	O
rs8099917GG	B:C0678941
)	O
with	O
a	O
frequency	O
of	O
30.1	O
,	O
21.9	O
,	O
and	O
20.5	O
%	O
,	O
respectively	O
.	O

In	O
patients	O
with	O
heterozygous	O
variant	B:C0678941
rs12979860CT	O
,	O
the	O
additional	O
genotyping	O
of	O
rs8099917	O
contributed	O
to	O
increase	O
the	O
sustained	O
virologic	I:C4050171
response	I:C4050171
rate	O
.	O

In	O
patients	O
with	O
heterozygous	O
variant	O
rs12979860CT	B:C0678941
,	O
the	O
additional	O
genotyping	O
of	O
rs8099917	O
contributed	O
to	O
increase	O
the	O
sustained	O
virologic	I:C4050171
response	I:C4050171
rate	O
.	O

In	O
patients	O
with	O
heterozygous	O
variant	O
rs12979860CT	O
,	O
the	O
additional	O
genotyping	B:C3178894
of	O
rs8099917	O
contributed	O
to	O
increase	O
the	O
sustained	O
virologic	I:C4050171
response	I:C4050171
rate	O
.	O

In	O
patients	O
with	O
heterozygous	O
variant	O
rs12979860CT	O
,	O
the	O
additional	O
genotyping	O
of	O
rs8099917	B:C0678941
contributed	O
to	O
increase	O
the	O
sustained	O
virologic	I:C4050171
response	I:C4050171
rate	O
.	O

In	O
patients	O
with	O
heterozygous	O
variant	O
rs12979860CT	O
,	O
the	O
additional	O
genotyping	O
of	O
rs8099917	O
contributed	O
to	O
increase	O
the	O
sustained	B:C4050171
virologic	I:C4050171
response	I:C4050171
rate	O
.	O

It	O
is	O
concluded	O
that	O
in	O
Cuban	B:C1553379
Hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
,	O
the	O
responder	O
homogeneous	O
variant	O
rs8099917TT	O
is	O
the	O
most	O
frequent	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
in	O
Cuban	O
Hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
,	O
the	O
responder	O
homogeneous	O
variant	O
rs8099917TT	O
is	O
the	O
most	O
frequent	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
in	O
Cuban	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	B:C0439663
patients	O
,	O
the	O
responder	O
homogeneous	O
variant	O
rs8099917TT	O
is	O
the	O
most	O
frequent	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
in	O
Cuban	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
,	O
the	O
responder	B:C0919876
homogeneous	O
variant	O
rs8099917TT	O
is	O
the	O
most	O
frequent	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
in	O
Cuban	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
,	O
the	O
responder	O
homogeneous	O
variant	B:C0678941
rs8099917TT	O
is	O
the	O
most	O
frequent	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
in	O
Cuban	O
Hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
,	O
the	O
responder	O
homogeneous	O
variant	O
rs8099917TT	B:C0678941
is	O
the	O
most	O
frequent	O
genotype	O
.	O

The	O
simultaneous	O
genotyping	B:C3178894
of	O
2	O
IL	O
-	I:C1425475
28B	I:C1425475
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	O
the	O
prediction	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	O
and	O
treatment	O
management	I:C0030677
.	O

The	O
simultaneous	O
genotyping	O
of	O
2	O
IL	B:C1425475
-	I:C1425475
28B	I:C1425475
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	O
the	O
prediction	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	O
and	O
treatment	O
management	I:C0030677
.	O

The	O
simultaneous	O
genotyping	O
of	O
2	O
IL	O
-	I:C1425475
28B	I:C1425475
single	B:C0752046
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	O
the	O
prediction	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	O
and	O
treatment	O
management	I:C0030677
.	O

The	O
simultaneous	O
genotyping	O
of	O
2	O
IL	O
-	I:C1425475
28B	I:C1425475
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	B:C0184511
the	O
prediction	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	O
and	O
treatment	O
management	I:C0030677
.	O

The	O
simultaneous	O
genotyping	O
of	O
2	O
IL	O
-	I:C1425475
28B	I:C1425475
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	O
the	O
prediction	O
of	O
sustained	B:C4050171
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	O
and	O
treatment	O
management	I:C0030677
.	O

The	O
simultaneous	O
genotyping	O
of	O
2	O
IL	O
-	I:C1425475
28B	I:C1425475
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	O
the	O
prediction	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	B:C0679006
and	O
treatment	O
management	I:C0030677
.	O

The	O
simultaneous	O
genotyping	O
of	O
2	O
IL	O
-	I:C1425475
28B	I:C1425475
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
could	O
improve	O
the	O
prediction	O
of	O
sustained	O
virologic	I:C4050171
response	I:C4050171
contributing	O
to	O
better	O
therapeutic	O
decisions	O
and	O
treatment	B:C0030677
management	I:C0030677
.	O

